NCT06258356View on ClinicalTrials.gov

Remimazolam in High Risk ERCP Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
the Severity and Duration of Intraoperative Hypotension
Interventions
DRUG

Remimazolam

novel ultra-short-acting benzodiazepine-like anesthetic.

DRUG

placebo

normal saline (compared to Remimazolam)

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT06258356 - Remimazolam in High Risk ERCP Patients | Biotech Hunter | Biotech Hunter